Janssen Emea

BEERSE, Belgium, March 25, 2011 - New data from an independent prospective study presented last week at the 19th European Congress of Psychiatry (EPA 2011) shows treatment with Risperdal(R) Consta(R) (risperidone long-acting injection (RLAI)) is associated with a lower risk of hospitalisation in patients with schizophrenia compared to treatment with other antipsychotics over a 12-month period.